Wuxi Apptec (603259:SSE) written Q&A, April 12, 2026 transcript

Transcript, summary, guidance, and what analysts pressed on from the Wuxi Apptec call on April 12, 2026.

FreeSee Wuxi Apptec's financials in GloomOpen in browser →Jump to the transcript
Held
April 12, 2026
Tone
Mildly positive0.35
Words
1,553
Tides capacity this year
130,000 litersthree new workshops underway
2025 overseas revenue share
87%
U.S. plant use
by the end of 2026gradual start-up expected
Testing and biology growth
positive growth in 2025; continue in 2026

Summary

Management framed growth around CRDMO capacity expansion and operational efficiency, while offering little quantified detail on pricing, capital allocation or customer concentration.

  • 130,000 liters of Tides capacity is targeted this year, with three new workshops under construction.
  • Testing and biology revenue are expected to return to growth in 2025 and continue growing in 2026.
  • The U.S. solid-dose and injectable plant is expected to enter use gradually by end-2026.

Guidance

  • 130,000 liters Tides capacity this year
  • Testing and biology revenue positive growth in 2025
  • Testing and biology revenue growth to continue in 2026
  • U.S. solid-dose and injectable plant gradually enters use by end-2026

What analysts pressed on

  • 01Pricing and demand: testing maintained healthy dynamic pricing, while biology will use flexible pricing; no new-order price trend was quantified.
  • 02U.S. Biological Act: management argued the company should not be listed and said it would correct misinformation, without quantifying exposure.
  • 03Financing and customer demand: early R&D funding has gradually recovered, especially for new molecules, with growth expected to continue.
  • 04Capital allocation: management cited steady revenue, profit and cash-flow growth but left dividend, buyback and investment trade-offs to board review.
  • 05FX and costs: the company reported a normalized hedging mechanism and process optimization, but gave no savings target or exchange-gain figure.
  • 06Customer concentration and orders: management cited its CRDMO model and customer-following strategy, without quantifying new-customer contributions or order cancellation risk.

Notable disclosures

  • 87%87% of 2025 revenue came from overseas customers, management disclosed in response to an FX question.
  • Three new Tides workshops are being built as total capacity targets 130,000 liters this year.
  • Testing’s adjusted non-IFRS gross margin improved quarter-on-quarter through 2025, despite prior-year price pressure.
  • Management did not provide a dividend floor, buyback plan, cost-reduction target or customer-concentration mitigation metrics.

Risks raised

  • U.S. Biological Act uncertainty may expose the company to listing risk; management said it would monitor developments and correct misinformation.
  • Testing and biology businesses faced order-price pressure that had reduced gross margins.
  • Foreign-exchange fluctuations affect performance, though management described normalized hedging and risk-management mechanisms.
  • Customer concentration and potential project delays or cancellations were raised, but management gave no quantified assessment of exposure.

Tone: Mildly positive 0.35

Management expressed confidence in continued demand and growth, but left several investor concerns unquantified and acknowledged regulatory and pricing uncertainties.

Who spoke

Company

  • Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde
  • Han MinSecretary of the Board of Directors, Yaoming Kangde
  • Shi MingChief Financial Officer, Yaoming Kangde
  • Yang QingExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

Full transcript

Analyst questions are marked with a bar. Timestamps are into the recording.

Prepared remarks

ModeratorSSE Roadshow Center

Ladies and gentlemen, investors and netizens, hello! Welcome to WuXi AppTec 2025 Annual Performance Presentation. This activity is sponsored by Wuxi WuXi AppTec New Drug Development Co., Ltd. and supported by the network platform provided by Shanghai Stock Exchange Information Network Co., Ltd. Thank you for your attention and participation. On March 24, Wuxi Yaoming Kangde New Drug Development Co., Ltd. published the Annual Report 2025. Investors can log on the website of Shanghai Stock Exchange (http://www.sse.com.cn/) or this platform (https://roadshow.sseinfo.com/).

View related announcements. In order to facilitate investors to have a more comprehensive and in-depth understanding of the company's annual operating results and financial situation in 2025, the company decided to hold the annual performance presentation of Yaoming Kangde in 2025. In today's event, the main members of the management of Yaoming Kangde visited the Shanghai Roadshow Center and will communicate with investors. Everyone is welcome to participate actively.

Questions and answers

Investor

I would like to ask this year's polypeptide production capacity upgrade plan? What was the revenue share of US, Chinese and European customers in the oligonucleotide and polypeptide business last year? Thank you

Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The company believes that the company will continue to promote the construction of production capacity, and the overall production capacity of Tides will reach 130,000 liters this year. At present, the company is steadily promoting the construction of three new Tides workshops. The company continues to rely on the ability and scale of CRDMO integrated service platform to better meet customer needs with efficient and extreme services. At present, the company only discloses the regional distribution of the overall revenue, and does not disclose the regional revenue of a single business sector separately.

Investor

Last year, the gross profit margin of the company's testing business and biology business declined significantly due to the impact of order prices. What is the price trend of new orders signed in the fourth quarter of last year and since this year? How to look forward to this year's demand trend? Thank you

Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The company believes that the revenue of the company's testing business and biology business will resume positive growth in 2025, and it is expected to continue to grow in 2026. Based on differentiated capability building and refined operation management, the testing business segment maintained a healthy dynamic pricing system, and the adjusted non-IFRS gross profit margin continued to improve quarter-on-quarter in 2025. The biology business segment will maintain a flexible pricing strategy to maximize the release of drainage value.

Investor

How to deal with the impact of the US Biological Act on companies and how to avoid the risk of being included in the dynamic list? Thank you!

Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The company believes: We believe that based on the facts, the company should not be included in any sanctions list. WuXi AppTec is listed in both Hong Kong and Shanghai and has a transparent corporate governance structure. WuXi AppTec is not owned or controlled by any government and is not affiliated with any governmental or military authority. WuXi AppTec has never been sanctioned or placed on any sanctions list by any government, including the United States government. The Company will continue to monitor the situation and take all necessary actions to correct misinformation and clarify misunderstandings.

At the same time, our top priority remains to continue to provide the quality of service and support our customers expect and to reduce the impact on patients around the world.

Investor

How does the company judge the global biomedical financing environment and customer demand this year?

Han MinSecretary of the Board of Directors, Yaoming Kangde

The company believes: We see that in the past few quarters, the global early R & D funds and investment and financing situation has been gradually recovering, especially in the new molecular related areas, the market demand has maintained a good growth, and the trend is expected to continue. We will continue to do a good job in capacity building and refined operation management to empower customers with extreme efficiency.

Investor

May I ask the latest progress and planned production time of our American factory? Thank you

Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The company believes that the US plant project is currently mainly involved in the production of solid preparations and injections, and is expected to be gradually put into use by the end of 2026.

Investor

Excuse me, what is the company's plan for the next three years? Can you elaborate on that?

Chen MinzhangExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The Company believes that: the Company will continue to focus on the core strategy of CRDMO, accelerate the global capacity building and capacity launch, continuously improve the efficiency of production and operation, create greater value for customers and shareholders, and strive to bring more new and good drugs to patients around the world, so as to realize the vision of "no difficult drugs and incurable diseases in the world" as soon as possible.

Investor

The company intends to pay 15.79 yuan (including tax) per 10 shares, with a total dividend of 4.712 billion yuan and a dividend rate of about 30%. Ask the CFO: -What is the sustainability basis of the high dividend policy? If we increase investment in technology or overseas mergers and acquisitions in the future, will the dividend ratio be adjusted dynamically? Is there a minimum dividend commitment? -Is there an enhancement of shareholder value through share repurchases? If implemented, the repurchase scale plan and the source of funds?

How to balance repurchase expenditure and capital expenditure needs?

Shi MingChief Financial Officer, Yaoming Kangde

The Company believes that the revenue, profit and cash flow of the Company will maintain steady growth, and high-quality performance returns will continue to be used for business development, talent incentives and shareholder returns. The management of the company will recommend the best plan for capital allocation to the board of directors based on the comprehensive evaluation of the actual situation.

Investor

Chief Financial Officer: What is the percentage of the company's overseas revenue? Exchange rate fluctuations have a significant impact on performance. -How much is the exchange gain and loss in 2025? How to hedge exchange rate risk through financial instruments? Will you consider more localized settlement or adjust the pricing strategy in the future? -As raw material and labor costs continue to rise, how can companies control costs through technology upgrades (e.g., automation, AI) or supply chain optimization? Is there a quantitative target (e.g. X% cost reduction over the next three years)?

Shi MingChief Financial Officer, Yaoming Kangde

The company believes that in 2025, the company's revenue from overseas customers will account for 87%. The company has been adhering to a prudent financial policy, and has established a normalized foreign exchange management mechanism and hedging strategy for exchange rate risk, in order to improve the predictability of the company's performance. The company continues to focus on the CRDMO business model, using new technologies and methods to continuously optimize the production process, and further promote fine management and operation.

The company's financial performance over the years has also fully verified the continuous improvement of operating efficiency and the continuous release of economies of scale.

Investor

The top ten customers of the company account for a large proportion of revenue and have a high degree of customer concentration. Excuse me -How to reduce the risk of dependence on large customers? What is the expansion strategy and effect of small and medium customers and long tail customers (such as Biotech)?

What are the number of new customers and the proportion of revenue contribution in 2025? -The amount of orders in hand was 59.887 billion yuan (continuing business), an increase of 41.2% over the same period last year, but there was a risk of project delay or cancellation in the industry. How does the company assess the enforceability and risk of the order? Is there a dynamic adjustment mechanism to ensure income stability?

Yang QingExecutive Director and Co-Chief Executive Officer, Yaoming Kangde

The Company believes that: the Company has been practicing the unique integrated, end-to-end CRDMO business model, implementing the strategy of following science, following customers and following molecules, so that the Company has the ability to continuously serve high-quality, high-value projects and innovative drug molecules.

ModeratorSSE Roadshow Center

Dear investors and netizens, the annual performance presentation of WuXi AppTec 2025 is drawing to a close. We invite guests from listed companies to make concluding remarks.

Han MinSecretary of the Board of Directors, Yaoming Kangde

Due to time constraints, the WuXi AppTec 2025 Annual Results Presentation has come to an end. I am very pleased to discuss and communicate with you on the company's industry situation, business situation and other aspects, and sincerely thank all investors for their warm and friendly exchanges and their continuous attention and ardent expectations for WuXi AppTec! After the meeting, investors are welcome to further communicate with us through diversified ways such as investor relations telephone, e-mail and SSE e-interaction.

ModeratorSSE Roadshow Center

This is the successful conclusion of the annual performance presentation of WuXi AppTec 2025. Thank you for the active participation of investors and netizens. If you have further questions, you can keep communicating with the company through the e interactive platform of Shanghai Stock Exchange. Thank you!

Other Wuxi Apptec earnings calls

  • Q2 2026 earnings call

    Management framed growth as increasingly supported by later-stage molecule progression, rising capacity utilization and operating efficiency.

    Aug 28, 2026Confident0.82
  • written Q&A, August 27, 2026

    Management framed the raised outlook as demand-led pipeline conversion, while emphasizing execution, capacity readiness and resilience amid geopolitical and currency headwinds.

    Aug 28, 2026Positive0.48
  • written Q&A, November 11, 2025

    Management framed durable CRDMO demand and capacity expansion as the growth engine, while emphasizing policy uncertainty and declining to quantify near-term peptide ramp or pricing effects.

    Nov 12, 2025Mildly positive0.35
  • written Q&A, August 28, 2025

    Management framed the call around strong demand and execution, raising its full-year outlook while balancing shareholder returns with global capacity investment.

    Aug 29, 2025Confident0.75

All Wuxi Apptec transcripts

About this transcript

The call was held in another language and translated. The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.